Four FDA-approved HDAC inhibitors—vorinostat, romidepsin, belinostat, and panobinostat—demonstrate a pan-inhibitory effect on almost all HDAC members and have made significant progress in treating some hematological malignancies. This evidence concerns the gene HDAC9 and hematologic disorder.